1. Home
  2. MPU vs LGVN Comparison

MPU vs LGVN Comparison

Compare MPU & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPU

Mega Matrix Corp.

HOLD

Current Price

$0.31

Market Cap

42.4M

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.81

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPU
LGVN
Founded
1989
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Transportation Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.4M
34.0M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
MPU
LGVN
Price
$0.31
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
73.6K
379.1K
Earning Date
04-16-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.48
52 Week High
$4.44
$1.80

Technical Indicators

Market Signals
Indicator
MPU
LGVN
Relative Strength Index (RSI) 23.31 49.34
Support Level N/A $0.74
Resistance Level $1.00 $0.86
Average True Range (ATR) 0.06 0.07
MACD -0.02 0.01
Stochastic Oscillator 10.78 78.25

Price Performance

Historical Comparison
MPU
LGVN

About MPU Mega Matrix Corp.

Mega Matrix Corp is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: